- Report
- September 2025
- 250 Pages
Global
From €4017EUR$4,490USD£3,532GBP
- Report
- September 2025
- 250 Pages
Global
From €4017EUR$4,490USD£3,532GBP
- Report
- April 2025
- 175 Pages
Global
From €4017EUR$4,490USD£3,532GBP
- Report
- April 2025
- 175 Pages
Global
From €4017EUR$4,490USD£3,532GBP
- Report
- April 2025
- 175 Pages
Global
From €4017EUR$4,490USD£3,532GBP
- Report
- April 2025
- 250 Pages
Global
From €4017EUR$4,490USD£3,532GBP
- Report
- April 2025
- 250 Pages
Global
From €4017EUR$4,490USD£3,532GBP
- Report
- April 2025
- 250 Pages
Global
From €4017EUR$4,490USD£3,532GBP
- Report
- February 2025
- 200 Pages
Global
From €4017EUR$4,490USD£3,532GBP
- Report
- February 2025
- 200 Pages
Global
From €4017EUR$4,490USD£3,532GBP
- Report
- January 2025
- 200 Pages
Global
From €4017EUR$4,490USD£3,532GBP
- Report
- November 2025
- 310 Pages
Global
From €5233EUR$5,850USD£4,601GBP
- Report
- November 2025
- 224 Pages
Global
From €5233EUR$5,850USD£4,601GBP
- Report
- November 2025
- 285 Pages
Global
From €5233EUR$5,850USD£4,601GBP
- Report
- November 2025
- 374 Pages
Global
From €5233EUR$5,850USD£4,601GBP
- Report
- November 2025
- 419 Pages
Global
From €5233EUR$5,850USD£4,601GBP
- Report
- November 2025
- 577 Pages
Global
From €5233EUR$5,850USD£4,601GBP
- Report
- November 2025
- 108 Pages
Global
From €5233EUR$5,850USD£4,601GBP
- Report
- November 2025
- 285 Pages
Global
From €5233EUR$5,850USD£4,601GBP
- Report
- November 2025
- 166 Pages
Global
From €5233EUR$5,850USD£4,601GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more